FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 326:437-443 February 13, 1992 Number 7 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. Zidovudine is recommended for asymptomatic and early symptomatic human immunodeficiency virus (HIV) infection. The best time to initiate zidovudine treatment remains uncertain, however, and whether early treatment improves survival has not been established. METHODS. We conducted a multicenter, randomized, double-blind trial that compared early zidovudine therapy (beginning at 1500 mg per day) with late therapy in HIV-infected patients who were symptomatic and had CD4+ counts between 0.2 x 10(9) and 0.5 x 10(9) cells per liter (200 to 500 per cubic millimeter) at entry. Those assigned to late therapy initially received placebo and began zidovudine when their CD4+ counts fell below 0.2 x 10(9) per liter (200 per cubic millimeter) or when the acquired immunodeficiency syndrome (AIDS) developed. RESULTS. During a mean follow-up period of more than two years, there were 23 deaths in the early-therapy group (n = 170) and 20 deaths in the late-therapy group (n = 168) (P = 0.48; relative risk [late vs. early], 0.81; 95 percent confidence interval, 0.44 to 1.59). In the early-therapy group, 28 patients progressed to AIDS, as compared with 48 in the late-therapy group (P = 0.02; relative risk, 1.76; 95 percent confidence interval, 1.1 to 2.8). Early therapy increased the time until CD4+ counts fell below 0.2 x 10(9) per liter (200 per cubic millimeter), and it produced more conversions from positive to negative for serum p24 antigen. Early therapy was associated with more anemia, leukopenia, nausea, vomiting, and diarrhea, whereas late therapy was associated with more skin rash. CONCLUSIONS. In symptomatic patients with HIV infection, early treatment with zidovudine delays progression to AIDS, but in this controlled study it did not improve survival, and it was associated with more side effects.

Source Information

Department of Veterans Affairs Medical Centers, Baltimore.

This article has been cited by other articles:

• Gimlin, D. (2007). Accounting for Cosmetic Surgery in the USA and Great Britain: A Cross-cultural Analysis of Women's Narratives. Body Society 13: 41-60 [Abstract]  
• Knorr, A. L., Srivastava, R. (2005). Evaluation of HIV-1 kinetic models using quantitative discrimination analysis. Bioinformatics 21: 1668-1677 [Abstract] [Full Text]  
• King, J. T. Jr., Justice, A. C., Roberts, M. S., Chang, C.-C. H., Fusco, J. S. (2003). Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era. Med Decis Making 23: 9-20 [Abstract]  
• Jordan, R., Gold, L., Cummins, C., Hyde, C. (2002). Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 324: 757-757 [Abstract] [Full Text]  
• Schwarcz, S. K., Hsu, L. C., Vittinghoff, E., Katz, M. H. (2000). Impact of Protease Inhibitors and Other Antiretroviral Treatments on Acquired Immunodeficiency Syndrome Survival in San Francisco, California, 1987-1996. Am J Epidemiol 152: 178-185 [Abstract] [Full Text]  
• Morgan, D, Malamba, S S, Orem, J, Mayanja, B, Okongo, M, Whitworth, J A G (2000). Survival by AIDS defining condition in rural Uganda. Sex. Transm. Infect. 76: 193-197 [Abstract] [Full Text]  
• Easterbrook, P. J., Goodall, R. L., Babiker, A. G., Yu, L. M., Smith, D., Cooper, D. A., Gazzard, B. G. (1999). Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?. J Antimicrob Chemother 43: 379-388 [Abstract] [Full Text]  
• Makadon, H. J. (1999). An Asymptomatic 41-Year-Old Man With HIV Infection. JAMA 281: 739-744 [Full Text]  
• Owens, D. K., Brandeau, M. L., Sox, C. H. (1998). Effect of Relapse to High-Risk Behavior on the Costs and Benefits of a Program to Screen Women for Human Immunodeficiency Virus. Interfaces 28: 52-74 [Abstract]  
• Boscardin, W J., Taylor, J. M., Law, N. (1998). Longitudinal models for AIDS marker data. Stat Methods Med Res 7: 13-27 [Abstract]  
• Hammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., Haubrich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, M., Hirsch, M. S., Merigan, T. C., The AIDS Clinical Trials Group Study 175 Study Tea, (1996). A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter. NEJM 335: 1081-1090 [Abstract] [Full Text]  
• Phillips, A. N, Smith, G. D., Johnson, M. A (1996). For Debate: Will we ever know when to treat HIV infection?. BMJ 313: 608-610 [Full Text]  
• Moore, R. D., Keruly, J. C., Chaisson, R. E. (1996). Duration of the Survival Benefit of Zidovudine Therapy in HIV Infection. Arch Intern Med 156: 1073-1077 [Abstract]  
• Enger, C., Graham, N., Peng, Y., Chmiel, J. S., Kingsley, L. A., Detels, R., Munoz, A. (1996). Survival From Early, Intermediate, and Late Stages of HIV Infection. JAMA 275: 1329-1334 [Abstract]  
• Karp, C. L., Scott, I. U., Chang, T. S., Pflugfelder, S. C. (1996). Conjunctival Intraepithelial Neoplasia: A Possible Marker for Human Immunodeficiency Virus Infection?. Arch Ophthalmol 114: 257-261 [Abstract]  
• Owens, D. K., Nease, R. F. Jr, Harris, R. A. (1996). Cost-effectiveness of HIV Screening in Acute Care Settings. Arch Intern Med 156: 394-404 [Abstract]  
• O'Brien, W. A., Hartigan, P. M., Martin, D., Esinhart, J., Hill, A., Benoit, S., Rubin, M., Simberkoff, M. S., Hamilton, J. D. (1996). Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS. NEJM 334: 426-431 [Abstract] [Full Text]  
• Laraque, F., Greene, A., Triano-Davis, J. W., Altman, R., Lin-Greenberg, A. (1996). Effect of Comprehensive Intervention Program on Survival of Patients With Human Immunodeficiency Virus Infection. Arch Intern Med 156: 169-176 [Abstract]  
• Volberding, P. A., Lagakos, S. W., Grimes, J. M., Stein, D. S., Rooney, J., Meng, T.-C., Fischl, M. A., Collier, A. C., Phair, J. P., Hirsch, M. S., Hardy, W. D., Balfour, H. H., Reichman, R. C., The AIDS Clinical Trials Group, (1995). A Comparison of Immediate with Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults with CD4 Cell Counts of 500 or More per Cubic Millimeter. NEJM 333: 401-407 [Abstract] [Full Text]  
• Kinloch-de Loes, S., Hirschel, B. J., Hoen, B., Cooper, D. A., Tindall, B., Carr, A., Saurat, J.-H., Clumeck, N., Lazzarin, A., Mathiesen, L., Raffi, F., Antunes, F., von Overbeck, J., Luthy, R., Glauser, M., Hawkins, D., Baumberger, C., Yerly, S., Perneger, T. V., Perrin, L. (1995). A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection. NEJM 333: 408-413 [Abstract] [Full Text]  
• Curtis, J. R., Paauw, D. S., Wenrich, M. D., Carline, J. D., Ramsey, P. G. (1995). Physicians' Ability to Provide Initial Primary Care to an HIV-Infected Patient. Arch Intern Med 155: 1613-1618 [Abstract]  
• Dolin, R., Amato, D. A., Fischl, M. A., Pettinelli, C., Beltangady, M., Liou, S.-h., Brown, M. J., Cross, A. P., Hirsch, M. S., Hardy, W. D., Mildvan, D., Blair, D. C., Powderly, W. G., Para, M. F., Fife, K. H., Steigbigel, R. T., Smaldone, L., AIDS Clinical Trials Group, , National Institute of Allergy and Infectious Disea, , National Institutes of Health, , Bristol-Myers Squibb, , Crumpacker, C. S., Cooley, T., Mitsuyaso, R. T., John, R., Sanders, C., Reitman, D., Hewitt, R., Reichman, R. C., Gelb, L. D., McGuire, M. L., Jones, M., Neidig, J. L., Zwickl, B., Hartman, P. B., Roarke, M. E., Burk, R. A., Fuhrer, J., Somogyi, K. A., Sepkowitz, K., Telzak, E. E., McAuliffe, V. J., Valentine, F. T., Vasquez, M., Merigan, T. C., Katzenstein, D., Fessell, J., Havlir, D. V., Richman, D. D., Spector, S. A., Kahn, J. O., Johnson, L., Coleman, R., Ho, M., McMahon, D., Pazin, G., Antoniskis, D., McNamara, B., Diamond, D., Collier, A. C., Paradise, M. A., Wald, A., DePaolis-Jones, A., Henry, K., Waskin, H. A., Hyslop, N. E. Jr, Mushatt, D. M., Zachary, J. A., Soeiro, R., Harris, C., Zingman, B., Giordano, M. F., Sledz, S., Murray, H. W., Carey, J. T., Davis, T. L., Bagby, B., Kessler, H. A., Murphy, R. I., Hirschtick, R. E., Cheeseman, S. H., Lai, K. K., Fairchild, P. G., Ehmann, W. C., Zurlo, J. J., Millard, R., Troiani, L., Heggen, A. A., van der Horst, C. M., McKinley, G. F., Grieco, M. H., Kolatch, B. R., Goldsmith, J. C., Gomperts, E. D., Woods, L. M., Grue, L., Mayjo, K., Becker, R. L., Jayaweera, D. T., Rolfe, L., Cole, J., Jermano, J. (1995). Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine. Arch Intern Med 155: 961-974 [Abstract]  
• Fisher, E. S., Welch, H. G. (1995). The Future of the Department of Veterans Affairs Health Care System. JAMA 273: 651-655 [Abstract]  
• Berman, D. S., Wenglin, B. D. (1994). The Efficacy of Zidovudine Is Time Limited. JAMA 272: 1001-1001 [Abstract]  
• Musicco, M., Lazzarin, A., Nicolosi, A., Gasparini, M., Costigliola, P., Arici, C., Saracco, A., Italian Study Group on HIV Heterosexual Transmissi, (1994). Antiretroviral Treatment of Men Infected With Human Immunodeficiency Virus Type 1 Reduces the Incidence of Heterosexual Transmission. Arch Intern Med 154: 1971-1976 [Abstract]  
• Volberding, P. A., Lagakos, S. W., Grimes, J. M., Stein, D. S., Balfour, H. H. Jr, Reichman, R. C., Bartlett, J. A., Hirsch, M. S., Phair, J. P., Mitsuyasu, R. T., Fischl, M. A., Soeiro, R., the AIDS Clinical Trials Group of the National Ins, , Pettinelli, C. B., Martinez, A. I., Liou, S.-H., Henry, K., Simpson, M., DePaolis-Jones, A., Hewitt, R. G., Blair, D. C., Packard, M. V., Fowler, C., Crumpacker, C. S., Allan, J. D., Fitch, H. F., Dybeck, K., Coleman, R., Jacobson, M., Phair, J. P., Murphy, R., Benson, C., Hardy, W. D., Chafey, S. A., Kruger, S., Reese, J., Dale, E., Harris, C., Steigbigel, N., Becker, R. L., Rexroad, V. E., Feinberg, J. E., Spector, S. A., Richman, D. D., Snyder, R., Merigan, T. C. Jr, Fessel, J., Katzenstein, D., Zachary, J. A., Mushatt, D. M., Hyslop, N. E. Jr, Collier, A. C., Corey, L., Coombs, R. W., Para, M. F., Fass, R. J., Whitacre, C., Sacks, H. S., Mildvan, D., Mendoza, H., Fife, K., Powderly, W. G., Gelb, L. D., Klebert, M., Leedom, J. M., Liggins, M., Quesada, N., Wong, B., Brinkdopke, J., Hoelle, M., Gocke, D. J., McAuliffe, V. J., Valentine, F. T., Dowling, J., Wallace, M., PaulJarrett, V., Cargill, V., McKinley, G. F., Grieco, M. H., Polsky, B., Brown, D. C., van der Horst, C., Fiscus, S., Ragan, D., Cheeseman, S. H., Fairchild, P. G., Lai, K. K., Ho, M., McMahon, D., Armstrong, J. A., Eyster, M. E., Ehmann, W. C., Irwin, D., Steigbigel, R. T., Fuhrer, J., Tenzler, R., Ponticello, L., Giordano, M. F., Murray, H. W. (1994). The Duration of Zidovudine Benefit in Persons With Asymptomatic HIV Infection: Prolonged Evaluation of Protocol 019 of the AIDS Clinical Trials Group. JAMA 272: 437-442 [Abstract]  
• Turner, B. J., Hecht, F. M., Ismail, R. B. (1994). CD4+ T-Lymphocyte Measures in the Treatment of Individuals Infected With Human Immunodeficiency Virus Type 1: A Review for Clinical Practitioners. Arch Intern Med 154: 1561-1573 [Abstract]  
• Lundgren, J D, Pedersen, C, Clumeck, N, Gatell, J M, Johnson, A M, Ledergerber, B, Vella, S, Phillips, A, Nielsen, J O (1994). Survival differences in European patients with AIDS, 1979-89. BMJ 308: 1068-7103 [Abstract] [Full Text]  
• Osmond, D., Charlebois, E., Lang, W., Shiboski, S., Moss, A. (1994). Changes in AIDS Survival Time in Two San Francisco Cohorts of Homosexual Men, 1983 to 1993. JAMA 271: 1083-1087 [Abstract]  
• Lundgren, J. D., Phillips, A. N., Pedersen, C., Clumeck, N., Gatell, J. M., Johnson, A. M., Ledergerber, B., Vella, S., Nielsen, J. O., Clumeck, N., DeWit, S., Sommereijns, B., Nielsen, J. O., Lundgren, J., Nielsen, T., Pedersen, C., Jensen, G., Skinhoj, P., Bentsen, K., Gerstoft, J., Melbye, M., Ranki, A., Valle, S.-L., Katlama, C., Berlureau, P., Dietrich, M., Schwander, S., Goebel, F.-D., Kosmidis, J., Stergiou, G., Gouzia, T., Papadopoulos, A., Banhegyi, D., Mulcahy, F., Yust, I., Ben-Ishai, Z., Bentwich, Z., Sacks, T., Maayan, S., Vella, S., Chiesi, A., Ancarani, F., Scalise, G., Bertaggia, A., Francavilla, E., Calonghi, G., Nuova, A. S. M., Emilia, R., Cargnel, A., Arlotti, M., Ciammarughi, R., Colomba, A., DeLalla, F., Fassio, P., Ferlini, A., Fiaccadori, F., Pasetti, G., Giannelli, F., Grillone, W., Lazzarin, A, Monforte, A. D., Mignani, E., Nunnari, A., Ortona, L., Panichi, G., Pauluzzi, S., Piersantelli, N., Ranieri, S., Ricciardiello, P., Roscioli, B., Soranzo, M., Hemmer, R., Danner, S., Bloemkolk, D., Antunes, F., Proenca, R., Gonzalez-Lahoz, J., Martinez-Blanco, L., Clotet, B., Gatell, J., Buira, E., Miro, J., Pehrson, P., Luthy, R., Ledergerber, B., Olsson, K., Glauser, M., Hirschel, B., Johnson, A., Hawkes, S., Phillips, A., Barton, S., Morcinek, J., Pinching, A., Coleman, D., Gjprup, I., Lundgren, J., Nielsen, J., Nieport, C., Pedersen, C., Teglbjaerg, L., Thornval, A. (1994). Comparison of Long-term Prognosis of Patients With AIDS Treated and Not Treated With Zidovudine. JAMA 271: 1088-1092 [Abstract]  
• Phair, J. P. (1994). Effectiveness of Zidovudine in Treatment of Advanced HIV Infection. JAMA 271: 1121-1122 [Abstract]  
• Lenderking, W. R., Gelber, R. D., Cotton, D. J., Cole, B. F., Goldhirsch, A., Volberding, P. A., Testa, M. A., The AIDS Clinical Trials Group, (1994). Evaluation of the Quality of Life Associated with Zidovudine Treatment in Asymptomatic Human Immunodeficiency Virus Infection. NEJM 330: 738-743 [Abstract] [Full Text]  
• Smith, G D, Egger, M (1994). Who benefits from medical interventions?. BMJ 308: 72-4 [Full Text]  
• Sande, M. A., Carpenter, C. C. J., Cobbs, C. G., Holmes, K. K., Sanford, J. P., the National Institute of Allergy and Infectious D, , Sande, M. A., Carpenter, C. C. J., Cobbs, C. G., Coombs, R. W., Fleming, T. R., Holmes, K. K., Denison, R., Gail, M. H., Greaves, W. L., Hirsch, M. S., Luskin-Hawk, R., Mildvan, D., Nelson, C. A., Phair, J. P., Sanford, J. P., Schooley, R., Torres, R. G., Vazquez, R., Deyton, L., Jermano, J., Koziol, J., Pettinelli, C., Katz, D. (1993). Antiretroviral Therapy for Adult HIV-lnfected Patients: Recommendations From a State-of-the-Art Conference. JAMA 270: 2583-2589 [Abstract]  
• Cooper, D. A., Gatell, J. M., Kroon, S., Clumeck, N., Millard, J., Goebel, F.-D, Bruun, J. N., Stingl, G., Melville, R. L., Gonzalez-Lahoz, J., Stevens, J. W., Fiddian, A. P., The European-Australian Collaborative Group, (1993). Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter. NEJM 329: 297-303 [Abstract] [Full Text]  
• Hirsch, M. S., D'Aquila, R. T. (1993). Therapy for Human Immunodeficiency Virus Infection. NEJM 328: 1686-1695 [Full Text]  
• Jewett, J. F., Hecht, F. M. (1993). Preventive Health Care for Adults With HIV Infection. JAMA 269: 1144-1153 [Abstract]  
• Koch, M. A., Volberding, P. A., Lagakos, S. W., Booth, D. K., Pettinelli, C., Myers, M. W. (1992). Toxic Effects of Zidovudine in Asymptomatic Human Immunodeficiency Virus-Infected Individuals With CD4+ Cell Counts of 0.50x109/L or Less: Detailed and Updated Results From Protocol 019 of the AIDS Clinical Trials Group. Arch Intern Med 152: 2286-2292 [Abstract]  
• McLeod, G. X., Hammer, S. M. (1992). Zidovudine: Five Years Later. ANN INTERN MED 117: 487-501 [Abstract]  
• Gelber, R. D., Lenderking, W. R., Cotton, D. J., Cole, B. F., Fischl, M. A., Goldhirsch, A., Testa, M. A. (1992). Quality-of-Life Evaluation in a Clinical Trial of Zidovudine Therapy in Patients with Mildly Symptomatic HIV Infection. ANN INTERN MED 116: 961-966 [Abstract]